Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Monrovia California, California. The company went IPO on 2008-12-29. The firm is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics Immunotherapy, Inc. and Biogenysis, Inc.